Steven Saccaro is an Oncology physician affiliated with Ochsner Medical Center. OpenAlex indexes 10 publications with 205 citations (h-index 5).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
1211 Coolidge Blvd Ste 100
Lafayette, LA 705032638
Telephone
337-289-8400Registry record last updated 15 Nov 2018.
Industry payments
36 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Novartis Pharmaceuticals CorporationProgram year202510 payments
- E.R. Squibb & Sons, L.L.C.Program year20255 payments
- Celgene CorporationProgram year20255 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
52.4%Aromatase Inhibitor22.6%Letrozole72%Anastrozole17%Exemestane11%Part D<11 patientsKinase inhibitor8.6%Imbruvica44%Ibrance29%Calquence27%Part D<11 patients+ 6 more classes in this area
Metabolism & gastrointestinal
14.4%Serotonin-3 Receptor Antagonist6.5%Ondansetron Hcl54%Ondansetron Odt46%Part D<11 patientsCorticosteroid5.3%Prednisone100%Part D≥12 patients+ 1 more class in this area
Dermatology
8.6%Herpesvirus Nucleoside Analog DNA Polymerase Inhibitor8.6%Acyclovir100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Multidimensional biomarker predicts disease control in response to immunotherapy in recurrent or metastatic head and neck squamous-cell carcinoma
Journal of Cancer Research and Clinical Oncology
2023 - Amethyst NSCLC trial: Phase 2, parallel-arm study of receptor tyrosine kinase (RTK) inhibitor, MGCD265, in patients (pts) with advanced or metastatic non-small cell lung cancer (NSCLC) with activating genetic alterations in mesenchymal-epithelial transition factor (<i>MET</i>).
Journal of Clinical Oncology
2016 - Randomized double-blind evaluation of dronabinol for the prevention of chemotherapy-induced nausea.
Journal of Clinical Oncology
2012
Similar KOLs
Other experts from the same institution or the same specialty.
Lawrence Blonde, MD
Ochsner Medical Center
Hector Ventura, MD
Ochsner Medical Center
George Pankey, MD
Ochsner Medical Center
Tyrone Collins, MD
Ochsner Medical Center
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”